⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK

Official Title: Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy

Study ID: NCT00216034

Conditions

Gastric Cancer

Study Description

Brief Summary: A randomized controlled study is conducted on patients with resected gastric cancer assigned to postoperative adjuvant therapy of TS-1 alone or PSK combined with TS-1, with the objective to examine or validate the outcome, QOL and prognostic factors (host and tumor factors), and explore the factors enhancing the antitumor effect of TS-1.

Detailed Description: The 5-year survival after gastric cancer surgery remains poor as the cancer advances to stages II, IIIA, IIIB and IV. Tegafur-gimeracil-oteracil potassium (TS-1) is used as the first line treatment for advanced and recurrent gastric cancer. But TS-1 is accompanied by an adverse drug reaction of bone marrow suppression that is not readily seen in conventional oral fluoropyrimidines. Among randomized controlled trials on postoperative adjuvant chemotherapy for gastric cancer, the beneficial results of survival rates using Krestin (PSK) in combination with chemotherapy have been reported. With the objective to enhance the antitumor effect of TS-1 and to improve the QOL of patients, we have planned to validate the clinical significance of combined PSK and TS-1 therapy as postoperative adjuvant therapy for gastric cancer, using in principle the TS-1 regimen of 2-week dosing 1-week off for 6 months followed by 2-week dosing 2-week off for 6 months.

Eligibility

Minimum Age: 20 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

University of Fukui Hospital, Eiheiji, Fukui, Japan

National Hospital Organization Fukui Hospital, Tsuruga, Fukui, Japan

Shakaihoken Kobe Central Hospital, Kobe, Hyogo, Japan

Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan

Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan

Kanazawa Redcross Hospital, Kanazawa, Ishikawa, Japan

Kanazawa Medical University Hospital, Uchinada, Ishikawa, Japan

Fukuchiyama City Hospital, Fukuchiyama, Kyoto, Japan

Kyoto Ohashi General Hospital, Fushimi, Kyoto, Japan

Houyu hospital, Joyo, Kyoto, Japan

National Hospital Organization Maizuru Medical Center, Maizuru, Kyoto, Japan

Saiseikai Kyoto Hospital, Nagaokakyo, Kyoto, Japan

Nantan General Hospital, Nantan, Kyoto, Japan

Rokujizo Hospital, Uji, Kyoto, Japan

Second Okamoto General Hospital, Uji, Kyoto, Japan

Kyoto Prefectural Yosanoumi Hospital, Yosano, Kyoto, Japan

Marutamachi Hospital, Nishinokyokurumazaka-cho, Nakagyou-ku Kyoto, Japan

Osaka City University Hospital, Asahi-machi, Osaka Abeno-ku, Japan

Sumitomo Hospital, Nakanoshima, Osaka Kita-ku, Japan

Matsushita Memorial Hospital, Moriguchi, Osaka, Japan

Midorigaoka Hospital, Takatsuki, Osaka, Japan

Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

Saiseikai Shigaken Hospital, Ritto, Shiga, Japan

Shimane University Hospital, Izumo, Shimane, Japan

Saiseikai Takaoka Hospital, Takaoka, Toyama, Japan

Kouseiren Takaoka Hoapital, Takaoka, Toyama, Japan

Toyama Rosai Hospital, Uozu, Toyama, Japan

Yatsuo General Hospital, Yatsuo, Toyama, Japan

Kitade Hospital, Gobou, Wakayama, Japan

Fukui Cardio Vascular Center, Fukui, , Japan

Fukui General Hospital, Fukui, , Japan

Fukui Saiseikai Hospital, Fukui, , Japan

Gifu Municipal Hospital, Gifu, , Japan

Gifu Prefectural General Medical Center, Gifu, , Japan

Gifu University Hospital, Gifu, , Japan

University Hospital, Kyoto Prefectural University of Medicine, Kyoto, , Japan

Nishijin Hospital, Kyoto, , Japan

Kyoto First Red Cross Hospital, Kyoto, , Japan

Nara City Hospital, Nara, , Japan

Osaka Railway hospital, Osaka, , Japan

Toyama Prefectural Central Hospital, Toyama, , Japan

Contact Details

Name: Koichi Miwa, MD, PhD

Affiliation: Hokuriku-Kinki Immunochemotherapy Study Group

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: